Precision Biosearch

Our Co-founder, Jemma Challinor, presents at the OBN Awards 2022

Precision BioSearch is delighted to present Kevin Lee, the CEO of Bicycle Therapeutics with the ‘Best Established Biotech Company’ award at the OBN Awards 2022.

 

The OBN Award ceremony was held at the Royal Lancaster and included 36 short-listed companies across 11 categories. Other finalists for the “Best Established Biotech Company” award included Touchlight and C4X Discovery, nominated for the second year running.

 

This award recognises an established biotech organisation making a significant impact on patients, stands out from the competition, has achieved excellent levels of funding & revenue generation, prominent levels of clinical trial activity and success, along with plenty of developing partnerships and collaborations – all led by an outstanding team. 

 

The Bicycle Therapeutics team was nominated for their companies’ broad achievement against all criteria of this category; they are working within an area of major medical need and have a very novel and exciting approach.  They have excellent fundraising, partnerships, and industry collaborations in place, and scored well on trials and product development.  They have great news flow, with an impressive and broadly implemented EDI strategy.    

 

Kevin Lee commented, “Extremely proud to watch this team go from strength to strength. Thank you Bicycle.”

 

About Bicycle Therapeutics: (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC®) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

 

For more information, visit: www.bicycletherapeutics.com

 

Posted on : 22nd November 2022

scroll to top